Back to discover

Protein / target

Cyclin-dependent kinase 4

Encoded byCDK4P11802Homo sapiensSwiss-Prot
UniProt: P11802Ensembl: ENSG00000135446HGNC: HGNC:1773NCBI Gene: 1019
Clinically validated
Therapeutic maturity
5
Approved medicines
Open Targets target-level
View by indication →
30
Clinical trials
Small-molecule tractable
Druggability
Approved Drug

Protein at a glance

Biological role

Cyclin-dependent protein serine/threonine kinase

Strongest disease association

Melanoma, cutaneous malignant, susceptibility to, 3

Via encoding gene CDK4 · Genetic evidence · score 0.80

Therapeutic position

Established drug target

Small molecules

Research activity

Emerging research

10 papers · latest 2025

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

Ser/Thr-kinase component of cyclin D-CDK4 (DC) complexes that phosphorylate and inhibit members of the retinoblastoma (RB) protein family including RB1 and regulate the cell-cycle during G(1)/S transition.

View complete UniProt function annotation

Ser/Thr-kinase component of cyclin D-CDK4 (DC) complexes that phosphorylate and inhibit members of the retinoblastoma (RB) protein family including RB1 and regulate the cell-cycle during G(1)/S transition. Phosphorylation of RB1 allows dissociation of the transcription factor E2F from the RB/E2F complexes and the subsequent transcription of E2F target genes which are responsible for the progression through the G(1) phase. Hypophosphorylates RB1 in early G(1) phase. Cyclin D-CDK4 complexes are major integrators of various mitogenenic and antimitogenic signals. Also phosphorylates SMAD3 in a cell-cycle-dependent manner and represses its transcriptional activity. Component of the ternary complex, cyclin D/CDK4/CDKN1B, required for nuclear translocation and activity of the cyclin D-CDK4 complex

Subcellular location

CytoplasmNucleusNucleus membrane
Domains and Gene Ontology detail (29)

Domains & features

Protein kinase

Gene Ontology

  • Cbicellular tight junction
  • Cchromatin
  • Ccyclin D1-CDK4 complex
  • Ccyclin D2-CDK4 complex
  • Ccyclin-dependent protein kinase holoenzyme complex
  • Ccytoplasm
  • Ccytosol
  • Cnuclear membrane
  • Cnucleolus
  • Cnucleoplasm
  • Cnucleus
  • Ctranscription regulator complex

303 aa · 34 kDa · 2 isoforms

Biological roles

Reactome v97

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Oncogenic signallingReactomeCell-cycle regulationGOCell proliferation & survivalGOTranscriptional regulationUniProt · GO · ReactomeKinase signallingGO
View supporting evidence

Oncogenic signalling

  • ·Oncogene Induced Senescence
  • ·Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4
  • ·Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6

Cell-cycle regulation

  • ·G1/S transition of mitotic cell cycle
  • ·G2/M transition of mitotic cell cycle
  • ·positive regulation of G2/M transition of mitotic cell cycle

Cell proliferation & survival

  • ·positive regulation of cell population proliferation

Transcriptional regulation

  • ·Ser/Thr-kinase component of cyclin D-CDK4 (DC) complexes that phosphorylate and inhibit…
  • ·transcription regulator complex
  • ·regulation of gene expression
  • ·regulation of transcription initiation by RNA polymerase II

Kinase signalling

  • ·cyclin-dependent protein kinase holoenzyme complex
  • ·cyclin-dependent protein serine/threonine kinase activity
  • ·cyclin-dependent protein serine/threonine kinase regulator activity
  • ·protein serine kinase activity
View underlying pathways (19)
SCF(Skp2)-mediated degradation of p27/p21
Oxidative Stress Induced Senescence
Senescence-Associated Secretory Phenotype (SASP)
Oncogene Induced Senescence
RMTs methylate histone arginines
Transcriptional regulation of white adipocyte differentiation
Cyclin D associated events in G1
Ubiquitin-dependent degradation of Cyclin D
PTK6 Regulates Cell Cycle
Transcriptional regulation by RUNX2
Meiotic recombination
Transcriptional regulation of granulopoiesis
Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4
Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6
Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Interaction neighbourhood

STRING v12.0

Proteins with the strongest functional or physical association. Node size and line weight reflect STRING confidence; hover or select a partner to inspect one association.

CCNL2CDKN2DRB1CCND1CDKN2ACCNA2CDKN1BCCND2CCND3CDKN1ACDK4

10 strongest partners — larger node and heavier line mean higher confidence

Functional and physical associations from STRING v12.0. Only associations with this protein are drawn — partner-to-partner links are not part of this evidence.

Approved medicines with mapped indications

2 medicines · 2 areas

Approved therapies targeting this protein, grouped by what they are approved to treat — the disease-first view of the medicines below. Relationships come from the canonical approved-indication graph (ChEMBL phase-4), the same source as the drug cards.

Breast Neoplasms2 medicines
abemaciclibpalbociclib
Broader indication categories (1)
Neoplasms2 medicines
abemaciclibpalbociclib

Broad umbrella indications (e.g. “Neoplasms”). Shown here because every medicine also appears under a more specific disease above — kept for completeness, de-emphasised for clarity.

5 medicines meet Open Targets' target-level approved-medicine definition; the 2 shown here are those on this page with a canonical approved disease indication in the graph. Approved indications from ChEMBL (phase-4), via the canonical drug→disease graph.

Drugs targeting this protein

3

How approved and investigational drugs engage this protein — mechanism and action type, direct vs complex targeting, and how broadly each acts across other targets. A drug-first view (the section above groups the approved ones disease-first); direct binders with few recorded targets are listed first.

palbociclib
Narrow target profileApprovedInhibitor

Cyclin-dependent kinase 4/cyclin D1 inhibitor

Indicated for Breast Neoplasms, Neoplasms

Direct interaction with this protein · 1 of 3 recorded protein targets — narrow recorded profile

abemaciclib
Narrow target profileApprovedInhibitor

Cyclin-dependent kinase 4 inhibitor

Indicated for Breast Neoplasms, Neoplasms

Direct interaction with this protein · 1 of 2 recorded protein targets — narrow recorded profile

ribociclib
Narrow target profilePhase 3Inhibitor

Cyclin-dependent kinase 4 inhibitor

Direct interaction with this protein · 1 of 2 recorded protein targets — narrow recorded profile

ChEMBL mechanism, action type, target identity and approved indications. Open Targets clinical status.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene CDK4

Gene-level evidence surfaced through the gene CDK4that encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Breast Neoplasms
0.87Well supported

Clinical evidence dominant · Open Targets 0.63

Melanoma, cutaneous malignant, susceptibility to, 3
0.83Well supported

Genetic evidence dominant · Open Targets 0.70

Familial melanoma
0.82Well supported

Genetic evidence dominant · Open Targets 0.58

Small Cell Lung Carcinoma
0.76Well supported

Clinical evidence dominant · Open Targets 0.59

Neoplasms
0.69Moderately supported

Clinical evidence dominant · Open Targets 0.54

View evidence synthesis (5)
Breast NeoplasmsWell supported
0.87
agreement 0.76–0.98
Clinical55%Somatic mutation22%Pathway12%Literature11%

Open Targets aggregate 0.63 · 4 independent evidence families

Melanoma, cutaneous malignant, susceptibility to, 3Well supported
0.83
agreement 0.71–0.95
Genetic87%Animal model13%Literature0%Genetic literaturedup

Open Targets aggregate 0.70 · 3 independent evidence families · 1 not counted as duplicate

Familial melanomaWell supported
0.82
agreement 0.70–0.94
Genetic85%Animal model13%Literature3%Genetic literaturedup

Open Targets aggregate 0.58 · 3 independent evidence families · 1 not counted as duplicate

Small Cell Lung CarcinomaWell supported
0.76
agreement 0.64–0.88
Clinical69%Somatic mutation21%Literature11%

Open Targets aggregate 0.59 · 3 independent evidence families

NeoplasmsModerately supported
0.69
agreement 0.53–0.84
Clinical81%Literature19%

Open Targets aggregate 0.54 · 2 independent evidence families

This ranking differs from Open Targets' own: re-weighting moves genetically-evidenced diseases above more heavily co-mentioned ones. The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations
Melanoma, cutaneous malignant, susceptibility to, 30.70
Breast Neoplasms0.63
Small Cell Lung Carcinoma0.59
Familial melanoma0.58
Neurodegenerative Diseases0.55
Alzheimer's Disease0.54
Neoplasms0.54
Multiple Sclerosis0.53

Drug development

17 compounds recorded · 5 approved · 12 in clinical development

Open Targets' development universe — every compound recorded against the target at any stage, not all approved medicines. Distinct from the 3 drugs that target this protein in Forefront's canonical graph (2 with a mapped approved indication, shown above): these count different sets and are not a subset relation.

View all recorded compounds (10)
AT-7519Phase 2
MILCICLIBPhase 2
AZD-5438Phase 1
RGB-286638Phase 1
TRILACICLIB DIHYDROCHLORIDEApproval
PALBOCICLIBApproval
PHA-793887Phase 1
ABEMACICLIBApproval
RIBOCICLIBPhase 3
ALVOCIDIBPhase 3

Open Targets known-drugs universe. Drug name and highest clinical stage only — the disease relationship is NOT read from this slice (it carries trial-context noise); approved indications come from the canonical graph above.

Tractability

Small molecules — Strong

Approved Drug and Structure with Ligand support this modality.

Protein degraders — Emerging

Feasibility evidence (literature and database ubiquitination) — no clinical-stage drug of this modality recorded.

View underlying tractability evidence (9)
SM · Approved DrugSM · Structure with LigandSM · High-Quality LigandSM · High-Quality PocketSM · Druggable FamilyPR · LiteraturePR · Database UbiquitinationPR · Half-life DataPR · Small Molecule Binder

Raw Open Targets tractability assessment buckets, by modality.

Clinical trials

30

Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein. Ranked by active status, then clinical phase and recency, and spread across the targeting drugs.

SERAFA-1: A Single Arm, Open Label, Multicentre, Phase IIIb Study Of Camizestrant Plus Ribociclib in 1st Line Treatment of ER Positive, HER2-negative Advanced Breast Cancer PatientsPHASE3

RECRUITING · via ribociclib · NCT07647328

A Randomised, Open-Label, Phase III Study of Saruparib (AZD5305) Plus Camizestrant Compared With Physician's Choice CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant for the First-Line Treatment of Patients With BRCA1, BRCA2, or PALB2 Mutations and Hormone Receptor Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified) Advanced Breast Cancer (EvoPAR-Breast01)PHASE3

RECRUITING · via abemaciclib · NCT06380751

A Phase III Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of GDC-9545 Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Patients With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast CancerPHASE3

ACTIVE_NOT_RECRUITING · via palbociclib · NCT04546009

A Phase 2, Randomized, Open-Label Dose Optimization and Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY4064809 Combined With a CDK4/6 Inhibitor and Endocrine Therapy in Adults With HR+, HER2-Advanced Breast Cancer With a PIK3CA Mutation Who Received No Prior Treatment for Advanced Breast Cancer (PIKALO-2)PHASE3

RECRUITING · via ribociclib · NCT07174336

View all trials (26)
A Phase 3 Randomized, Double-Blind, Active-Controlled Study of Palazestrant With Ribociclib Versus Letrozole With Ribociclib for the First-Line Treatment of ER+, HER2- Advanced Breast Cancer (OPERA-02)PHASE3

RECRUITING · via ribociclib · NCT07085767

CYCLONE 3: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abemaciclib in Combination With Abiraterone Plus Prednisone in Men With High-Risk Metastatic Hormone-Sensitive Prostate CancerPHASE3

ACTIVE_NOT_RECRUITING · via abemaciclib · NCT05288166

SARC041: Phase 3 Randomized Double-Blind Study of Abemaciclib Versus Placebo in Patients with Advanced Dedifferentiated LiposarcomaPHASE3

ACTIVE_NOT_RECRUITING · via abemaciclib · NCT04967521

EMBER-3: A Phase 3, Randomized, Open-Label Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Patients With Estrogen Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With Endocrine TherapyPHASE3

ACTIVE_NOT_RECRUITING · via abemaciclib · NCT04975308

Adjuvant Dynamic Marker - Adjusted Personalized Therapy Comparing Endocrine Therapy Plus Ribociclib Versus Chemotherapy in Intermediate Risk, HR+/HER2- Early Breast CancerPHASE3

ACTIVE_NOT_RECRUITING · via ribociclib · NCT04055493

A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast CancerPHASE3

ACTIVE_NOT_RECRUITING · via abemaciclib · NCT03155997

PALbociclib CoLlaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+) / Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Early Breast CancerPHASE3

ACTIVE_NOT_RECRUITING · via palbociclib · NCT02513394

JUNIPER: A Randomized Phase 3 Study of Abemaciclib Plus Best Supportive Care Versus Erlotinib Plus Best Supportive Care in Patients With Stage IV NSCLC With a Detectable KRAS Mutation Who Have Progressed After Platinum-Based ChemotherapyPHASE3

ACTIVE_NOT_RECRUITING · via abemaciclib · NCT02152631

Abemaciclib Combined With FOLFOX/FOLFIRI Regimen in Patients With Advanced Colorectal Liver Metastases Cancer Who Failed Standard Two or Three-line TherapyPHASE2

ENROLLING_BY_INVITATION · via abemaciclib · NCT07441369

Phase II Minimal Residual Disease Study of Selective Estrogen Receptor Degrader Imlunestrant With Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Abemaciclib in Patients With ER+ Breast Cancer (MIRI)PHASE2

NOT_YET_RECRUITING · via abemaciclib · NCT07191717

The VIOLET Trial: A Pragmatic Phase II Study to Optimize Neoadjuvant Treatment and Surgical De-escalation in HR+/HER2- Early Breast Cancer Using Oncotype DX and AbemaciclibPHASE2

NOT_YET_RECRUITING · via abemaciclib · NCT07428018

A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Patients With Endocrine- Resistant Hormone-Receptor-Positive, HER2-Negative Advanced Breast Cancer With Chromosome 8P Loss and Without a PIK3CA MutationPHASE2

RECRUITING · via ribociclib · NCT07405801

Neoadjuvant Camrelizumab With Palbociclib for the Treatment of Resectable Esophageal Squamous Cell Carcinoma: A Single-Arm Phase 2 TrialPHASE2

NOT_YET_RECRUITING · via palbociclib · NCT07191977

A Phase Ib/II Multicenter, Open-Label, Randomized Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-4198 Alone and in Combination With Giredestrant in Comparison With Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive, HER2-Negative Breast Cancer Who Have Previously Progressed During or After a CDK4/6 InhibitorPHASE1/PHASE2

RECRUITING · via abemaciclib · NCT07100106

Phase Ib/II Trial of Ribociclib Plus Anastrozole in Patients With Hormone Receptor-Positive, HER2-Negative Metastatic or Recurrent Breast CancerPHASE1/PHASE2

RECRUITING · via ribociclib · NCT07164976

A Phase II, Randomization, Unblinded Study of ELacestrant in Combination With Abemaciclib or Elacestrant Alone In p53 Wild Type, Estrogen Receptor-positive Advanced or recurrenT Endometrial Cancer (ELITE)PHASE2

RECRUITING · via abemaciclib · NCT07209449

A Phase 1b/2 Trial of Afatinib Plus Palbociclib in Previously Treated Recurrent or Metastatic Esophageal Squamous Cell CarcinomaPHASE1/PHASE2

RECRUITING · via palbociclib · NCT06753747

A Phase II, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Neoadjuvant Treatment With Inavolisib Combinations in Patients With Untreated, Early-stage, PIK3CA-Mutated Breast CancerPHASE2

RECRUITING · via ribociclib · NCT07054190

SELECT: A Phase II Adjuvant Trial Evaluating the Impact of Omitting Chemotherapy Based on Patient's Selection for Moderate to High-Anatomical Risk, Low-Genomic Risk, ER-Positive, HER2- Negative Breast Cancer With a Combination Regimen of Ribociclib and Optimized Endocrine TherapyPHASE2

RECRUITING · via ribociclib · NCT06953882

A Phase Ib/II Study of the Mirdametinib in Combination With Palbociclib in Patients With Advanced Dedifferentiated LiposarcomaPHASE1/PHASE2

RECRUITING · via palbociclib · NCT06843967

A Phase II Clinical Study on Precision Treatment of Rare Tumours in China Guided by Patient-Derived Tumor Organoids (PDO) and Next-Generation Sequencing (NGS)PHASE2

NOT_YET_RECRUITING · via palbociclib · NCT06692491

A Phase 2 Trial of Maintenance Abemaciclib/Letrozole After Systemic Therapy in Patients With Advanced or Recurrent Estrogen Receptor Positive, Mismatch Repair Proficient, TP53 Wildtype Endometrial CancerPHASE2

RECRUITING · via abemaciclib · NCT06366347

A Pilot Study of Sequential ("First Strike, Second Strike") Therapies, Modeled on Evolutionary Dynamics of Anthropocene Extinctions, for Hormone Positive Metastatic Breast CancerPHASE2

RECRUITING · via ribociclib · NCT06409390

A Phase II Trial to Evaluate Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast CancerPHASE2

RECRUITING · via abemaciclib · NCT06179303

A Randomized Trial of Neratinib, A Pan-ERBB Inhibitor, Alone or in Combination With Palbociclib, a CDK4/6 Inhibitor, in Patients With HER2+ Gynecologic Cancers and Other Solid Tumors: A ComboMATCH Treatment TrialPHASE2

RECRUITING · via palbociclib · NCT06126276

Palbociclib and Binimetinib in RAS-Mutant Cancers: A ComboMATCH Treatment TrialPHASE2

ACTIVE_NOT_RECRUITING · via palbociclib · NCT05554367

ClinicalTrials.gov via the drug-target graph.

What's happening now

12

Recent therapeutic activity around this target — regulatory actions, clinical trials and safety signals for 3 drugs that target this protein, plus publications where such a drug is a genuine subject. Every item is reached indirectly through the drug, not the protein itself; incidental mentions (a paper that merely measures a drug) and press items are excluded.

  1. Trial status changed2026-07-22

    Phase I Study of the Pan-ERBB Inhibitor Neratinib Given in Combination With Everolimus, Palbociclib, or Trametinib in Advanced Cancer Subjects With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation

    Status changed to Terminated · ClinicalTrials.gov · via palbociclib

  2. Trial status changed2026-07-21

    A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy and in Combination With Anticancer Therapies in Participants With Selected Advanced Solid Tumors

    Status changed to Active, not recruiting · ClinicalTrials.gov · via palbociclib

  3. Indication expanded2026-07-13

    Indication expansion: ABEMACICLIB (NDA208716)

    fda · regulatory · fda · via abemaciclib

  4. Trial status changed2026-07-06

    PIKture-01: First-in-Human Study of the PI3KαH1047R Mutant-Selective Inhibitor OKI-219 as Monotherapy in Participants With Advanced Solid Tumors and as Part of Combination Therapy in Participants With Advanced Breast Cancer

    Status changed to Active, not recruiting · ClinicalTrials.gov · via ribociclib

  5. Indication expanded2026-07-01

    Indication expansion: RIBOCICLIB (NDA209092)

    fda · regulatory · fda · via ribociclib

  6. Indication expanded2026-06-24

    Indication expansion: PALBOCICLIB (NDA207103)

    fda · regulatory · fda · via palbociclib

  7. Indication expanded2026-06-24

    Indication expansion: PALBOCICLIB (NDA212436)

    fda · regulatory · fda · via palbociclib

  8. Regulatory approval2026-06-19

    Approval: Palbociclib Viatris (EMA)

    ema · regulatory · ema · via palbociclib

  9. New publication2024-05-08
    Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3.

    Annals of oncology : official journal of the European Society for Medical Oncology · 2024 · 161 citations · Europe PMC · via abemaciclib

  10. New publication2024-01-02
    Efficacy, safety, and predictive model of Palbociclib in the treatment of HR-positive and HER2-negative metastatic breast cancer.

    BMC cancer · 2024 · 28 citations · Europe PMC · via palbociclib

  11. New publication2023-12-01
    Open-label, phase II, multicenter study of lasofoxifene plus abemaciclib for treating women with metastatic ER+/HER2- breast cancer and an ESR1 mutation after disease progression on prior therapies: ELAINE 2.

    Annals of oncology : official journal of the European Society for Medical Oncology · 2023 · 37 citations · Europe PMC · via abemaciclib

  12. New publication2023-09-01
    Efficacy, safety, and biomarker analysis of nivolumab in combination with abemaciclib plus endocrine therapy in patients with HR-positive HER2-negative metastatic breast cancer: a phase II study (WJOG11418B NEWFLAME trial).

    Journal for immunotherapy of cancer · 2023 · 48 citations · Europe PMC · via abemaciclib

Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.

Research activity

10 papers · to 2025

Papers linked directly to this protein. This is the protein's own literature — descriptor-derived papers are kept separate below.

Most cited

Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial.528 cites

Bidard FC · Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022

Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences.277 cites

Braal CL · Drugs · 2021

Recent progress of CDK4/6 inhibitors' current practice in breast cancer.90 cites

Wang X · Cancer gene therapy · 2024

Elacestrant in ER+, HER2- Metastatic Breast Cancer with ESR1-Mutated Tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy plus CDK4/6 Inhibitor and in Clinical Subgroups.56 cites

Bardia A · Clinical cancer research : an official journal of the American Association for Cancer Research · 2024

Abemaciclib Is Effective in Palbociclib-Resistant Hormone Receptor-Positive Metastatic Breast Cancers.38 cites

Navarro-Yepes J · Cancer research · 2023

Recent

Cytogenetic signatures favoring metastatic organotropism in colorectal cancer.

Golas MM · Nature communications · 2025

Elacestrant in ER+, HER2- Metastatic Breast Cancer with ESR1-Mutated Tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy plus CDK4/6 Inhibitor and in Clinical Subgroups.

Bardia A · Clinical cancer research : an official journal of the American Association for Cancer Research · 2024

Landscape of Baseline and Acquired Genomic Alterations in Circulating Tumor DNA with Abemaciclib Alone or with Endocrine Therapy in Advanced Breast Cancer.

Goetz MP · Clinical cancer research : an official journal of the American Association for Cancer Research · 2024

Recent progress of CDK4/6 inhibitors' current practice in breast cancer.

Wang X · Cancer gene therapy · 2024

DNA damage induced by CDK4 and CDK6 blockade triggers anti-tumor immune responses through cGAS-STING pathway.

Fan H · Communications biology · 2023

Cyclin D1-Cdk4 regulates neuronal activity through phosphorylation of GABAA receptors.

Pedraza N · Cellular and molecular life sciences : CMLS · 2023

CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.

Kohlmeyer JL · Clinical cancer research : an official journal of the American Association for Cancer Research · 2023

Abemaciclib Is Effective in Palbociclib-Resistant Hormone Receptor-Positive Metastatic Breast Cancers.

Navarro-Yepes J · Cancer research · 2023

Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial.

Bidard FC · Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022

Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences.

Braal CL · Drugs · 2021

Europe PMC papers linked directly to this protein.

Related family literature

5

Papers about “Cyclin-Dependent Kinases” — a broader family this protein belongs to. Shown as context; not counted as papers specifically about this protein.

Cyclin-dependent kinase inhibitors enhance programmed cell death protein 1 immune checkpoint blockade efficacy in triple-negative breast cancer by affecting the immune microenvironment.

Wu J · Cancer · 2024

via Cyclin-Dependent Kinases

Efficacy of Poly(ADP-ribose) Polymerase Inhibitors by Individual Genes in Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer: A US Food and Drug Administration Pooled Analysis.

Fallah J · Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024

via Cyclin-Dependent Kinases

Evaluating Immune Checkpoint Blockade in Metastatic Castration-Resistant Prostate Cancers with Deleterious CDK12 Alterations in the Phase 2 IMPACT Trial.

Nguyen CB · Clinical cancer research : an official journal of the American Association for Cancer Research · 2024

via Cyclin-Dependent Kinases

Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer.

Hussain M · The New England journal of medicine · 2020

via Cyclin-Dependent Kinases

Malignant glioma: genetics and biology of a grave matter.

Maher EA · Genes & development · 2001

via Cyclin-Dependent Kinases

Europe PMC literature, reached through curated HGNC family membership. Membership is a taxonomic relationship — it does not imply this protein participates in every mechanism these papers discuss.